The CAR T-cell therapy market for acute lymphoblastic
leukemia is poised for substantial growth, driven by the
anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL
(OBE-CEL), UCART22, WU-CART-007, UCART19, PBCAR0191, AUTO1/22, and
others, its promising efficacy in treating refractory and relapsed
cases. With ongoing research, expanding clinical trials, and
increasing approvals, the market is set to witness a surge in
adoption, offering renewed hope for patients battling this
aggressive form of leukemia.
LAS
VEGAS, May 22, 2024 /PRNewswire/ --
DelveInsight's CAR T-Cell Therapy for Acute Lymphoblastic
Leukemia Market Insights report includes a comprehensive
understanding of current treatment practices, CAR T-Cell therapy
for ALL emerging drugs, market share of individual therapies, and
current and forecasted market size from 2019 to 2032, segmented
into 7MM [the United States, the
EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan].
Key Takeaways from the CAR T-Cell Therapy for Acute
Lymphoblastic Leukemia Market Report
- According to DelveInsight's analysis, the market size for CAR
T-Cell therapy for ALL reached USD
75 million in 2021 across the 7MM.
- In the 7MM, the US accounted for the largest market size in
2021, with approximately USD 55
million.
- DelveInsight's analysis reveals that the total incident cases
of ALL in the US comprised ~6,200 in 2021.
- Leading CAR T-Cell therapy for ALL companies such as
AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE,
PRECISION BIOSCIENCES, and others are developing novel CAR
T-Cell therapies for NHL drugs that can be available in the CAR
T-Cell therapy for ALL market in the coming years.
- Promising CAR T-Cell therapies for NHL in the pipeline
include OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22, WU-CART-007,
UCART19, PBCAR0191, AUTO1/22, and others.
- CAR-T cells provide a long-term benefit with a one-time
treatment, avoiding the toxicity of salvage chemotherapy and
autologous transplant for patients with high-risk illnesses. The
approvals have altered the standard of care for high-risk patients
who are either primary refractory or have early recurrence
following front-line therapy.
Discover which therapies are expected to grab the major CAR
T-Cell therapy for ALL market share @ CAR T-Cell therapy
for ALL Market Report
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
Overview
Acute lymphocytic leukemia (ALL), alternatively known as acute
lymphoblastic leukemia, is a form of cancer impacting the blood and
bone marrow. It originates from immature white blood cells, or
lymphocytes, found in the bone marrow. This condition is
characterized by an excess production of these immature cells,
referred to as lymphoblasts or leukemic blasts. Consequently, the
bone marrow fails to produce sufficient red blood cells, normal
white blood cells, and platelets, leading to increased
vulnerability to anemia, recurrent infections, and easy bruising
and bleeding. The leukemic blasts can escape from the bone marrow
into the bloodstream and accumulate in various organs such as the
lymph nodes, spleen, liver, and central nervous system (including
the brain and spinal cord). Diagnostic methods for ALL typically
involve blood tests, bone marrow examinations, imaging procedures,
and analysis of spinal fluid.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
Epidemiology Segmentation
Among the gender-specific cases, males accounted for nearly
3,500 cases, while females accounted for 2,700 in the
US in 2021. Among the type-specific cases of ALL, the incident
cases of B-ALL accounted for nearly 85%, while that of T-ALL
accounted for nearly 15% in the US.
The CAR T-Cell therapy for ALL market report proffers
epidemiological analysis for the study period 2019–2032 in the 7MM
segmented into: total incident cases of ALL,
gender-specific cases of ALL, age-specific cases of ALL,
subtype-specific cases of ALL, genetic-mutation specific cases of
ALL, and total treated cases of ALL
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Treatment
Market
For years, conventional chemotherapy containing cytotoxic agents
has served as the primary treatment approach for adults with ALL.
However, this method poses significant risks including potentially
fatal complications such as infection, bleeding, thrombosis,
neuropathy, osteonecrosis, and the development of secondary cancers
like AML and MDS.
The landscape shifted dramatically with the introduction of
CAR-T cell therapy over a decade ago, initially successful in
treating pediatric ALL. Since then, there has been an explosion of
research into new CAR-T constructs and targets, as well as a deeper
understanding of CAR T-cell persistence and novel mechanisms of
antigen escape.
This evolution saw the approval of KYMRIAH (tisagenlecleucel,
or tisa-cel, by Novartis) for pediatric and young adult
patients who had undergone at least two prior lines of therapy,
followed by TECARTUS (brexucabtagene autoleucel, or brexu-cel,
by Kite) for adults experiencing their first relapse. CAR-T
cell therapy is poised to catalyze the next significant advancement
in leukemia immunotherapy.
TECARTUS, an immunotherapy, is developed to target
CD19-presenting cancer and normal B cells, altering one's T cells
genetically for the task. Studies have unveiled that once these
modified T cells engage with CD19-presenting cells, specific
domains like CD28 and CD3-zeta kickstart signaling processes,
activating the T cells, prompting their multiplication, empowering
them with effective capabilities, and inducing the release of
inflammatory agents. This orchestrated series of actions culminate
in the elimination of CD19-expressing cells. In October 2021, the FDA sanctioned TECARTUS for
adults with refractory or relapsed B-ALL. Similarly, the European
Commission approved it in September
2022.
KYMRIAH is an immunotherapy method that directs T cells
toward CD19-expressing cells, both cancerous and healthy, through
genetic modification. This involves modifying a patient's T cells
with a gene that encodes a chimeric antigen receptor (CAR), which
can identify and remove CD19-expressing cells. The CAR contains a
fragment of a mouse antibody that targets CD19 and is connected to
signaling parts inside the cell. When the CAR binds to CD19 on
cells, it triggers a series of actions that lead to the expansion,
activation, elimination of target cells, and persistence of the
modified T cells. KYMRIAH gained approval from the US FDA in
August 2017 for treating patients up
to 25 years old with relapsed or refractory B-cell acute
lymphoblastic leukemia (R/R B-ALL). Subsequent approvals were
obtained from the European Commission in August 2018 and the Ministry of Health, Labour
and Welfare in Japan in
March 2019.
To know more about CAR T-Cell therapy for ALL treatment
guidelines, visit @ CAR T-Cell Therapy for Acute Lymphoblastic
Leukemia Management
Emerging CAR T-Cell Therapies for NHL and Key
Companies
- OBECABTAGENE AUTOLEUCEL (OBE-CEL): AUTOLUS THERAPEUTICS
- UCART22: CELLECTIS
- WU-CART-007: WUGEN
- UCART19: CELLECTIS/SERVIER/ALLOGENE
- PBCAR0191: PRECISION BIOSCIENCES
- AUTO1/22: AUTOLUS THERAPEUTICS
Learn more about the FDA-approved CAR T-Cell therapy for ALL @
Drugs for CAR T-Cell therapy for ALL
Treatment
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market
Dynamics
CAR T-cell therapy has revolutionized the treatment landscape
for acute lymphoblastic leukemia, introducing a paradigm shift in
cancer therapy. The market dynamics for CAR T-cell therapy in ALL
are marked by a delicate balance of innovation, accessibility,
and affordability. Despite its remarkable efficacy, challenges
persist, primarily concerning its high cost and logistical
complexities, which impact market penetration and patient
access.
The dynamic interplay between pharmaceutical companies,
healthcare providers, and regulatory bodies shapes the
trajectory of the CAR T-cell therapy market for ALL. Pharmaceutical
companies are engaged in fierce competition to develop novel
therapies with enhanced efficacy and safety profiles while
navigating regulatory pathways for approvals. Simultaneously,
healthcare providers are tasked with optimizing treatment
protocols, managing adverse events, and ensuring equitable
access to this cutting-edge therapy for eligible patients.
The evolving landscape of reimbursement policies and
healthcare infrastructures further influences market dynamics.
Efforts to secure reimbursement and streamline distribution
channels are pivotal for enhancing the adoption of CAR T-cell
therapy in ALL. As stakeholders collaborate to address these
challenges, the market for CAR T-cell therapy continues to evolve,
driven by a shared commitment to improving patient outcomes and
advancing the standard of care for ALL.
CAR T-Cell Therapy
for Acute Lymphoblastic Leukemia Market Report
Metrics
|
Details
|
Study Period
|
2019–2032
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
CAR T-Cell Therapy for
Acute Lymphoblastic Leukemia Market Size in 2021
|
USD 75
Million
|
Key CAR T-Cell Therapy
for Acute Lymphoblastic Leukemia Companies
|
AUTOLUS THERAPEUTICS,
CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES,
and others
|
Key CAR T-Cell Therapy for Acute Lymphoblastic
Leukemia in Pipeline
|
OBECABTAGENE AUTOLEUCEL
(OBE-CEL), UCART22, WU-CART-007, UCART19, PBCAR0191,
AUTO1/22, and others
|
Scope of the CAR T-Cell Therapy for Acute
Lymphoblastic Leukemia Market Report
- Therapeutic Assessment: CAR T-Cell Therapy for Acute
Lymphoblastic Leukemia current marketed and emerging
therapies
- CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
Market Dynamics: Key Market Forecast Assumptions of
Emerging CAR T-Cell Therapy for Acute Lymphoblastic
Leukemia Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis,
Conjoint Analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, CAR T-Cell
Therapy for Acute Lymphoblastic Leukemia Market Access and
Reimbursement
Discover more about CAR T-Cell therapy for ALL drugs in
development @ CAR T-Cell Therapy for Acute Lymphoblastic
Leukemia Clinical Trials
Table of Contents
1
|
KEY INSIGHTS
|
2
|
REPORT
INTRODUCTION
|
3
|
EXECUTIVE SUMMARY OF
CAR-T IN ALL
|
4
|
KEY EVENTS
|
5
|
EPIDEMIOLOGY AND MARKET
METHODOLOGY
|
6
|
CAR-T IN ALL MARKET
OVERVIEW AT A GLANCE
|
7
|
DISEASE BACKGROUND AND
OVERVIEW
|
8
|
CURRENT TREATMENT
PRACTICES: ALL
|
9
|
EPIDEMIOLOGY AND
PATIENT POPULATION OF 7MM
|
10
|
PATIENT
JOURNEY
|
11
|
MARKETED
DRUGS
|
12
|
EMERGING
DRUGS
|
13
|
CAR-T IN ALL: THE 7MM
ANALYSIS
|
14
|
UNMET NEEDS
|
15
|
SWOT
ANALYSIS
|
16
|
KOL VIEWS
|
17
|
MARKET ACCESS AND
REIMBURSEMENT
|
18
|
APPENDIX
|
19
|
DELVEINSIGHT
CAPABILITIES
|
20
|
DISCLAIMER
|
21
|
ABOUT
DELVEINSIGHT
|
Related Reports
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
Pipeline
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline
Insight – 2024 report provides comprehensive insights
about the pipeline landscape, pipeline drug profiles, including
clinical and non-clinical stage products, and the key CAR
T-Cell therapy for ALL companies, including Autolus,
PersonGen Biotherapeutics, Pepromene Bio, Inc., Actinium
Pharmaceuticals, among others.
CAR T-Cell Therapy Market
CAR T-Cell Therapy Market Insights, Epidemiology, and Market
Forecast – 2032 report delivers an in-depth understanding of
the disease, historical and forecasted epidemiology, as well as the
market trends, market drivers, market barriers, and key CAR T-cell
therapy companies, including CytoAgents, Genentech, Incyte
Corporation, Caribou Biosciences, Chimeric Therapeutics, Allogene
Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics,
Synthekine, Janssen Research & Development, SecuraBio, ImmPACT
Bio, A2 Biotherapeutics, Gracell Biopharmaceuticals, Wugen, Sana
Biotechnology, Oncternal Therapeutics, Vor Biopharma, CARsgen
Therapeutics, Autolus Limited, Arcellx, Kite, Novartis, Lyell
Immunopharma, ImmPACT Bio, Tmunity Therapeutics, Poseida
Therapeutics, Precigen, AffyImmune Therapeutics, 2seventy bio,
Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech,
Miltenyi Biomedicine, Beam Therapeutics, among others.
CAR T-Cell Therapy Competitive Landscape
CAR T-cell Therapy Competitive Landscape –
2024 report provides comprehensive insights about the
pipeline and current landscape, pipeline and marketed drug
profiles, and the key CAR T-cell therapy companies, including
Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences,
Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics,
Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell
Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy
Bio-medicine Technology, Sinobioway Cell Therapy, Tessa
Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine,
Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical
Science and Technology, Carsgen Therapeutics, Cellular Biomedicine
Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula
Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang
Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara
Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics
Biotech Company, Yake Biotechnology, Minerva Biotechnologies,
Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou),
Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai
GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio,
among others.
Acute Lymphocytic Leukemia Market
Acute Lymphocytic Leukemia Market Insights, Epidemiology, and
Market Forecast – 2032 report delivers an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key acute lymphocytic leukemia companies, including
Novartis AG, Gracell Biotechnologies, Pfizer, Bristol-Myers
Squibb, Hebei Senlang Biotechnology, PersonGen BioTherapeutics
(Suzhou) Co Ltd., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market-to-register-stunning-growth-by-2032-predicts-delveinsight--key-companies---autolus-therapeutics-cellectis-wugen-servier-allogene-precision-biosciences-302152395.html
SOURCE DelveInsight Business Research, LLP